These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 39030807)

  • 1. Efficacy and Safety of Fruquintinib-Based Treatment in Patients with Refractory Bone and Soft Tissue Sarcoma after Developing Resistance to Several TKIs: A Multicenter Retrospective Study.
    Yang C; Li B; Dong S; Xu J; Sun X; Liang X; Liu K; Sun K; Yang Y; Ji T; Ye Z; Xie L; Tang X
    Orthop Surg; 2024 Oct; 16(10):2380-2390. PubMed ID: 39030807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of fruquintinib-based therapy in patients with advanced or metastatic sarcoma.
    Zhou C; Qian G; Wang Y; Li H; Shen Z; Zheng S
    Cancer Med; 2024 Jul; 13(13):e7438. PubMed ID: 38967496
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of fruquintinib in patients with previously treated metastatic colorectal cancer: a phase Ib study and a randomized double-blind phase II study.
    Xu RH; Li J; Bai Y; Xu J; Liu T; Shen L; Wang L; Pan H; Cao J; Zhang D; Fan S; Hua Y; Su W
    J Hematol Oncol; 2017 Jan; 10(1):22. PubMed ID: 28103904
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Retrospective study on the efficacy and safety of low dose apatinib in reversing chemotherapy resistance in sarcoma].
    Ye T; Yuan SY; Fan L; Feng LW; Chen YT; Chen J
    Zhonghua Yi Xue Za Zhi; 2022 Aug; 102(31):2435-2440. PubMed ID: 36000372
    [No Abstract]   [Full Text] [Related]  

  • 5. Real-world experience of tyrosine kinase inhibitors in children, adolescents and adults with relapsed or refractory bone tumours: A Canadian Sarcoma Research and Clinical Collaboration (CanSaRCC) study.
    Peretz Soroka H; Vora T; Noujaim J; Marcoux N; Cohen-Gogo S; Alcindor T; Holloway C; Rodrigues C; Karachiwala H; Alvi S; Lee U; Cheng S; Banerji S; Oberoi S; Feng X; Smrke A; Simmons C; Razak AA; Gupta AA
    Cancer Med; 2023 Sep; 12(18):18872-18881. PubMed ID: 37724607
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of anlotinib in patients with unresectable or metastatic bone sarcoma: A retrospective multiple institution study.
    Liu Z; Gao S; Zhu L; Wang J; Zhang P; Li P; Zhang F; Yao W
    Cancer Med; 2021 Nov; 10(21):7593-7600. PubMed ID: 34564939
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of fruquintinib as third- or further-line therapy for patients with advanced bone and soft tissue sarcoma: a multicenter retrospective study.
    Ding X; Liu Y; Zhang Y; Liang J; Li Q; Hu H; Zhou Y
    Anticancer Drugs; 2023 Aug; 34(7):877-882. PubMed ID: 36539356
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Fruquintinib After Two Prior Chemotherapy Regimens in Chinese Patients With Advanced Nonsquamous Non‒Small-Cell Lung Cancer.
    Lu S; Chang J; Liu X; Shi J; Lu Y; Li W; Yang JJ; Zhou J; Wang J; An T; Yang L; Liu Z; Zhou X; Chen M; Hua Y; Su W
    J Clin Oncol; 2018 Apr; 36(12):1207-1217. PubMed ID: 29528793
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer: The FRESCO Randomized Clinical Trial.
    Li J; Qin S; Xu RH; Shen L; Xu J; Bai Y; Yang L; Deng Y; Chen ZD; Zhong H; Pan H; Guo W; Shu Y; Yuan Y; Zhou J; Xu N; Liu T; Ma D; Wu C; Cheng Y; Chen D; Li W; Sun S; Yu Z; Cao P; Chen H; Wang J; Wang S; Wang H; Fan S; Hua Y; Su W
    JAMA; 2018 Jun; 319(24):2486-2496. PubMed ID: 29946728
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of RS plus bevacizumab versus RS plus fruquintinib as the third-line therapy in patients with refractory metastatic colorectal cancer: A real-world propensity score matching study.
    Zhou Y; Xu Q; Wang J; Leng WB; Cao P; Chen Y; Luo DY; Qiu M; Liu J
    J Evid Based Med; 2024 Sep; 17(3):667-674. PubMed ID: 39327543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Apatinib for advanced sarcoma: results from multiple institutions' off-label use in China.
    Xie L; Guo W; Wang Y; Yan T; Ji T; Xu J
    BMC Cancer; 2018 Apr; 18(1):396. PubMed ID: 29625604
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Retrospective review of the activity and safety of apatinib and anlotinib in patients with advanced osteosarcoma and soft tissue sarcoma.
    Tian Z; Liu H; Zhang F; Li L; Du X; Li C; Yang J; Wang J
    Invest New Drugs; 2020 Oct; 38(5):1559-1569. PubMed ID: 32100146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-World Efficacy and Safety of Cabozantinib and Vandetanib in Advanced Medullary Thyroid Cancer.
    Koehler VF; Adam P; Frank-Raue K; Raue F; Berg E; Hoster E; Allelein S; Schott M; Kroiss M; Spitzweg C
    Thyroid; 2021 Mar; 31(3):459-469. PubMed ID: 32781914
    [No Abstract]   [Full Text] [Related]  

  • 14. Regorafenib, TAS-102, or fruquintinib for metastatic colorectal cancer: any difference in randomized trials?
    Zhang Q; Wang Q; Wang X; Li J; Shen L; Peng Z
    Int J Colorectal Dis; 2020 Feb; 35(2):295-306. PubMed ID: 31848739
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic Effects of Fruquintinib Combined with Immune Checkpoint Inhibitors on Metastatic Colorectal Cancer.
    Xie MZ; Li YQ; Liang R; Huang SY; Qin SY; Hu BL
    J Gastrointest Cancer; 2024 Dec; 55(4):1620-1627. PubMed ID: 39316296
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Phase III, randomized, double-blind, placebo-controlled, multicenter study of fruquintinib in Chinese patients with advanced nonsquamous non-small-cell lung cancer - The FALUCA study.
    Lu S; Chen G; Sun Y; Sun S; Chang J; Yao Y; Chen Z; Ye F; Lu J; Shi J; He J; Liu X; Zhang Y; Liu Z; Fang J; Cheng Y; Hu C; Mao W; Hu Y; Gong Y; Shan L; Yang Z; Song Y; Li W; Bai C; Wang B; Ma R; Zheng Z; Liu M; Jie Z; Cao L; Liao W; Pan H; Huang D; Chen Y; Yang J; Qin S; Ma S; Liang L; Liu Z; Zhou J; Tao M; Huang Y; Qiu F; Huang Y; Guan S; Peng M; Su W
    Lung Cancer; 2020 Aug; 146():252-262. PubMed ID: 32592986
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Previous Use of Anti-Vascular Endothelial Growth Factor Receptor Agents Decreases Efficacy of Fruquintinib in Metastatic Colorectal Cancer Refractory to Standard Therapies.
    Wang L; Cao H; Jiang C; He W; You Y; Peng K; Jin Y; Xia L
    Front Oncol; 2020; 10():587692. PubMed ID: 33282739
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-dose ifosfamide as second- or third-line chemotherapy in refractory bone and soft tissue sarcoma patients.
    Lee SH; Chang MH; Baek KK; Han B; Lim T; Lee J; Park JO
    Oncology; 2011; 80(3-4):257-61. PubMed ID: 21734417
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FDA Approval Summary: Fruquintinib for the Treatment of Refractory Metastatic Colorectal Cancer.
    Fusco MJ; Casak SJ; Mushti SL; Cheng J; Christmas BJ; Thompson MD; Fu W; Wang H; Yoon M; Yang Y; Moore JN; Bi Y; Nan Y; Long CE; Auth D; Rahman NA; Tang S; Pazdur R; Fashoyin-Aje LA; Kluetz PG; Lemery SJ
    Clin Cancer Res; 2024 Aug; 30(15):3100-3104. PubMed ID: 38809262
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subgroup analysis by prior anti-VEGF or anti-EGFR target therapy in FRESCO, a randomized, double-blind, Phase III trial.
    Xu R; Qin S; Guo W; Bai Y; Deng Y; Yang L; Chen Z; Zhong H; Pan H; Shu Y; Yuan Y; Zhou J; Xu N; Liu T; Ma D; Wu C; Cheng Y; Xu J; Chen D; Li W; Sun S; Yu Z; Cao P; Li J; Chen H; Wang J; Wang S; Wang H; Wang N; Zhang B; Han R; Su W; Guo X; Li J
    Future Oncol; 2021 Apr; 17(11):1339-1350. PubMed ID: 33325251
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.